Drug Eluting Stent News and Research

RSS
A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.
Elixir Medical’s DESyne BD Novolimus Eluting Coronary Stent System receives CE Mark approval

Elixir Medical’s DESyne BD Novolimus Eluting Coronary Stent System receives CE Mark approval

Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe

Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe

HCRI announces successful completion of randomization in DAPT Study

HCRI announces successful completion of randomization in DAPT Study

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack

STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack

Kona Medical raises $30 million in Series C financing

Kona Medical raises $30 million in Series C financing

Results from Medtronic’s Resolute DES clinical study on CAD

Results from Medtronic’s Resolute DES clinical study on CAD

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Cook Medical introduces drug-eluting peripheral stent to treat lesions in the SFA

Cook Medical introduces drug-eluting peripheral stent to treat lesions in the SFA

Svelte completes enrollment in DIRECT drug-eluting stent study

Svelte completes enrollment in DIRECT drug-eluting stent study

SurModics second quarter revenue declines 8% to $12.2 million

SurModics second quarter revenue declines 8% to $12.2 million

Abbott, St. Jude Medical enter multi-year joint initiative for cardiovascular treatment technologies

Abbott, St. Jude Medical enter multi-year joint initiative for cardiovascular treatment technologies

Japanese MHLW approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Japanese MHLW approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

Medtronic Resolute DES found effective through two years

Medtronic Resolute DES found effective through two years

Symposium to cover latest breakthroughs in percutaneous treatment of CAD

Symposium to cover latest breakthroughs in percutaneous treatment of CAD

FDA approves Boston Scientific's ION and TAXUS Liberte paclitaxel-eluting stents

FDA approves Boston Scientific's ION and TAXUS Liberte paclitaxel-eluting stents

FDA approves Medtronic's Resolute Integrity DES to treat CAD

FDA approves Medtronic's Resolute Integrity DES to treat CAD

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

U.S. District Court rules in favor of Boston Scientific in PROMUS patent infringement case

U.S. District Court rules in favor of Boston Scientific in PROMUS patent infringement case